These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 26652893

  • 1. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [Abstract] [Full Text] [Related]

  • 3. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
    Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, Wang X, Culver K, Casciano R, Garrison LP.
    J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
    [Abstract] [Full Text] [Related]

  • 4. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
    Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.
    Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
    [Abstract] [Full Text] [Related]

  • 5. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [Abstract] [Full Text] [Related]

  • 6. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [Abstract] [Full Text] [Related]

  • 7. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
    Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.
    Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
    [Abstract] [Full Text] [Related]

  • 8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI.
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [Abstract] [Full Text] [Related]

  • 9. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A, Hamid AR, Mochtar CA, Umbas R.
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [Abstract] [Full Text] [Related]

  • 10. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B.
    Cochrane Database Syst Rev; 2020 Oct 14; 10(10):CD012796. PubMed ID: 33058158
    [Abstract] [Full Text] [Related]

  • 11. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ.
    Lancet Oncol; 2013 Dec 14; 14(13):1287-94. PubMed ID: 24206640
    [Abstract] [Full Text] [Related]

  • 12. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.
    Br J Cancer; 2014 Jun 10; 110(12):2821-8. PubMed ID: 24823696
    [Abstract] [Full Text] [Related]

  • 13. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G, Schmitz S, Broom RJ.
    J Cancer Res Clin Oncol; 2013 Nov 10; 139(11):1917-26. PubMed ID: 24037486
    [Abstract] [Full Text] [Related]

  • 14. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V, Lin X, Kalanovic D, Simantov R.
    Eur Urol; 2016 Dec 10; 70(6):1006-1015. PubMed ID: 27238653
    [Abstract] [Full Text] [Related]

  • 15. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    Soerensen AV, Donskov F, Kjellberg J, Ibsen R, Hermann GG, Jensen NV, Fode K, Geertsen PF.
    Eur Urol; 2015 Sep 10; 68(3):516-22. PubMed ID: 25533417
    [Abstract] [Full Text] [Related]

  • 16. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R, Fleury L, Nachbaur G, Maunoury F, Vanhille JL, Durand-Zaleski I.
    Curr Med Res Opin; 2017 Oct 10; 33(10):1755-1762. PubMed ID: 28748721
    [Abstract] [Full Text] [Related]

  • 17. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H.
    Anticancer Drugs; 2016 Jun 10; 27(5):383-97. PubMed ID: 26886011
    [Abstract] [Full Text] [Related]

  • 18. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B, Fu S, Meng J, Lister J, Karcher H.
    PLoS One; 2017 Jun 10; 12(9):e0184423. PubMed ID: 28886175
    [Abstract] [Full Text] [Related]

  • 19. Systemic therapy in metastatic renal cell carcinoma.
    Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K.
    World J Urol; 2017 Feb 10; 35(2):179-188. PubMed ID: 27277600
    [Abstract] [Full Text] [Related]

  • 20. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.
    Cancer Treat Rev; 2016 Nov 10; 50():109-117. PubMed ID: 27664394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.